All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
Inspra
Â
Topic mentions per year
Topic mentions per year
2003-2016
0
1
2
3
2003
2016
Related topics
Related topics
1 relation
Broader (1)
eplerenone
Related mentions per year
Related mentions per year
1994-2018
1990
2000
2010
2020
Inspra
eplerenone
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops.
Alexandre Matet
,
Alejandra L. Daruich
,
Francine Béhar-Cohen
Ophthalmic surgery, lasers & imaging retina
2017
Long-lasting postoperative macular edema is a therapeutic challenge. The authors report an efficient combination therapy of oral…Â
(More)
Is this relevant?
2016
2016
Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy
Francesco Pichi
,
Paola Carrai
,
Antonio Pasquale Ciardella
,
Francine Béhar-Cohen
,
Paolo Nucci
International Ophthalmology
2016
To evaluate the effect of oral spironolactone and eplerenone, two specific antagonists of the mineralocorticoid receptor, in…Â
(More)
Is this relevant?
2013
2013
Prostate effect in dogs with the aldosterone receptor blocker eplerenone.
Stuart Levin
,
Ellen McMahon
,
Annette John-Baptiste
,
Rosonald R Bell
Toxicologic pathology
2013
Eplerenone (Inspra) is an aldosterone receptor antagonist approved for the treatment of hypertension and heart failure after a…Â
(More)
Is this relevant?
Review
2006
Review
2006
Does eplerenone have a future in the management of hypertension in Europe?
Phillipe Gosse
,
R J Macfadyen
Journal of Human Hypertension
2006
Eplerenone (Inspra, Pfizer, New York, USA), a 9,11epoxy derivative of spironolactone, is the second aldosterone antagonist…Â
(More)
Is this relevant?
Review
2005
Review
2005
Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Katherine F. Croom
,
Greg L. Plosker
PharmacoEconomics
2005
Eplerenone (Inspra) is a selective aldosterone blocker. When added to standard medical therapy, eplerenone significantly improved…Â
(More)
Is this relevant?
2004
2004
Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure.
Jennifer M. Craft
Proceedings
2004
Eplerenone is the second oral aldosterone antagonist available in the USA for the treatment of essential hypertension and heart…Â
(More)
Is this relevant?
2004
2004
The evolution of aldosterone antagonists.
Susan M. Garthwaite
,
Ellen McMahon
Molecular and cellular endocrinology
2004
Since the isolation and purification of aldosterone from adrenal extracts 50 years ago (Experientia 9 (1953) 33), scientists have…Â
(More)
Is this relevant?
2004
2004
Eplerenone (Inspra) for hypertension.
Charles Taylor
American family physician
2004
Â
Is this relevant?
Review
2004
Review
2004
Aldosterone target organ protection by eplerenone.
Amy E Rudolph
,
Ricardo Rocha
,
Ellen McMahon
Molecular and cellular endocrinology
2004
The classical mineralocorticoid effect of aldosterone on unidirectional transepithelial sodium transport in the kidney was long…Â
(More)
Is this relevant?
2003
2003
Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
Louis Michael Prisant
,
Henry Krum
,
Barbara Roniker
,
Scott L Krause
,
Kaffa Fakouhi
,
Weizhong He
Journal of clinical pharmacology
2003
Since neither angiotensin-converting enzyme inhibitors (ACE-I) nor angiotensin II receptor blockers (ARB) can completely suppress…Â
(More)
Is this relevant?